متاح الآن! بحث تيليغرام 2025 — أهم رؤى العام 
JAMA (Journal of the American Medical Association)
الذهاب إلى القناة على Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
إظهار المزيد📈 نظرة تحليلية على قناة تيليجرام JAMA (Journal of the American Medical Association)
تُعد قناة JAMA (Journal of the American Medical Association) (@jamaupdates) في القطاع اللغوي الإنكليزية لاعباً نشطاً. يضم المجتمع حالياً 15 169 مشتركاً، محتلاً المرتبة 1 626 في فئة الطب والمرتبة 2 526 في منطقة الولايات المتحدة.
📊 مؤشرات الجمهور والحراك
منذ تأسيسه في невідомо، حقق المشروع نمواً سريعاً وجمع 15 169 مشتركاً.
بحسب آخر البيانات بتاريخ 09 يونيو, 2026، تحافظ القناة على نشاط مستقر. خلال آخر 30 يوماً تغيّر عدد الأعضاء بمقدار 543، وفي آخر 24 ساعة بمقدار 9، مع بقاء الوصول العام مرتفعاً.
- حالة التحقق: غير موثّقة
- معدل التفاعل (ER): يبلغ متوسط تفاعل الجمهور 4.43%. وخلال أول 24 ساعة من النشر يحصد المحتوى عادةً 2.15% من ردود الفعل نسبةً إلى إجمالي المشتركين.
- وصول المنشورات: يحصل كل منشور على متوسط 671 مشاهدة. وخلال اليوم الأول يجمع عادةً 325 مشاهدة.
- التفاعلات والاستجابة: يتفاعل الجمهور بانتظام؛ متوسط التفاعلات لكل منشور يبلغ 1.
- الاهتمامات الموضوعية: يركز المحتوى على مواضيع رئيسية مثل patient, disease, treatment, drug, guideline.
📝 الوصف وسياسة المحتوى
يصف المؤلف القناة بأنها مساحة للتعبير عن الآراء الذاتية:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
بفضل وتيرة التحديث المرتفعة (أحدث البيانات بتاريخ 10 يونيو, 2026) تحافظ القناة على حداثتها ومستوى وصول مرتفع. وتُظهر التحليلات تفاعلاً نشطاً من الجمهور، ما يجعلها نقطة تأثير مهمة ضمن فئة الطب.
15 169
المشتركون
+924 ساعات
+1037 أيام
+54330 أيام
جاري تحميل البيانات...
القنوات المماثلة
سحابة العلامات
الإشارات الواردة والصادرة
---
---
---
---
---
---
جذب المشتركين
يونيو '26
يونيو '26
+156
في 0 قنوات
مايو '26
+584
في 0 قنوات
Get PRO
أبريل '26
+437
في 0 قنوات
Get PRO
مارس '26
+217
في 0 قنوات
Get PRO
فبراير '26
+247
في 0 قنوات
Get PRO
يناير '26
+321
في 0 قنوات
Get PRO
ديسمبر '25
+277
في 0 قنوات
Get PRO
نوفمبر '25
+366
في 2 قنوات
Get PRO
أكتوبر '25
+164
في 0 قنوات
Get PRO
سبتمبر '25
+12
في 0 قنوات
Get PRO
أغسطس '25
+29
في 0 قنوات
Get PRO
يوليو '25
+30
في 0 قنوات
Get PRO
يونيو '25
+17
في 0 قنوات
Get PRO
مايو '25
+9
في 0 قنوات
Get PRO
أبريل '25
+5
في 0 قنوات
Get PRO
مارس '25
+17
في 0 قنوات
Get PRO
فبراير '25
+12
في 0 قنوات
Get PRO
يناير '25
+18
في 1 قنوات
Get PRO
ديسمبر '24
+237
في 0 قنوات
Get PRO
نوفمبر '24
+1 122
في 0 قنوات
Get PRO
أكتوبر '24
+1 120
في 0 قنوات
Get PRO
سبتمبر '24
+1 527
في 1 قنوات
Get PRO
أغسطس '24
+1 128
في 1 قنوات
Get PRO
يوليو '24
+1 216
في 0 قنوات
Get PRO
يونيو '24
+781
في 1 قنوات
Get PRO
مايو '24
+797
في 1 قنوات
Get PRO
أبريل '24
+808
في 1 قنوات
Get PRO
مارس '24
+821
في 2 قنوات
Get PRO
فبراير '24
+753
في 1 قنوات
Get PRO
يناير '24
+768
في 0 قنوات
Get PRO
ديسمبر '23
+716
في 1 قنوات
Get PRO
نوفمبر '23
+96
في 1 قنوات
Get PRO
أكتوبر '23
+86
في 0 قنوات
Get PRO
سبتمبر '23
+73
في 0 قنوات
Get PRO
أغسطس '23
+90
في 0 قنوات
Get PRO
يوليو '23
+107
في 0 قنوات
Get PRO
يونيو '23
+105
في 0 قنوات
Get PRO
مايو '23
+169
في 0 قنوات
Get PRO
أبريل '23
+128
في 0 قنوات
Get PRO
مارس '23
+84
في 0 قنوات
Get PRO
فبراير '23
+75
في 0 قنوات
Get PRO
يناير '23
+71
في 0 قنوات
Get PRO
ديسمبر '22
+74
في 0 قنوات
Get PRO
نوفمبر '22
+149
في 0 قنوات
Get PRO
أكتوبر '22
+90
في 0 قنوات
Get PRO
سبتمبر '22
+138
في 0 قنوات
Get PRO
أغسطس '22
+77
في 0 قنوات
Get PRO
يوليو '22
+50
في 0 قنوات
Get PRO
يونيو '22
+96
في 0 قنوات
Get PRO
مايو '22
+75
في 0 قنوات
Get PRO
أبريل '22
+80
في 0 قنوات
Get PRO
مارس '22
+65
في 0 قنوات
Get PRO
فبراير '22
+26
في 0 قنوات
Get PRO
يناير '22
+56
في 0 قنوات
Get PRO
ديسمبر '21
+44
في 0 قنوات
Get PRO
نوفمبر '21
+39
في 0 قنوات
Get PRO
أكتوبر '21
+61
في 0 قنوات
Get PRO
سبتمبر '21
+66
في 0 قنوات
Get PRO
أغسطس '21
+65
في 0 قنوات
Get PRO
يوليو '21
+96
في 0 قنوات
Get PRO
يونيو '21
+120
في 0 قنوات
Get PRO
مايو '21
+130
في 0 قنوات
Get PRO
أبريل '21
+812
في 0 قنوات
| التاريخ | نمو المشتركين | الإشارات | القنوات | |
| 10 يونيو | +23 | |||
| 09 يونيو | +9 | |||
| 08 يونيو | +8 | |||
| 07 يونيو | +18 | |||
| 06 يونيو | +13 | |||
| 05 يونيو | +25 | |||
| 04 يونيو | +22 | |||
| 03 يونيو | +9 | |||
| 02 يونيو | +19 | |||
| 01 يونيو | +10 |
منشورات القناة
Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850256
This randomized clinical trial evaluates the progression of coronary artery calcification compared with placebo over a 2-year period.
| 2 | Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850257
In this issue of JAMA Cardiology, Vossen et al report the results of a randomized clinical trial investigating whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) at a daily dose of 360 µg would delay progression of coronary artery calcification. Among 180 patients with baseline coronary artery calcium (CAC) scores of 50 to 400 Agatston units (AU), they observed a small but statistically significant slowing of CAC progression, measured as either AU or calcium mass score. | 128 |
| 3 | Cost Offset With Quadruple Therapy for Heart Failure
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850258
This economic evaluation examines Medicare-linked registry data to estimate the 1-year health care cost offset and net cost associated with using quadruple guideline-directed medical therapy after hospitalization for heart failure with reduced ejection fraction. | 122 |
| 4 | Neurological Manifestations in Adult Survivors of Ebola Virus Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850237
This cohort study evaluates the neurological health of adult survivors of Ebola virus disease over the course of a 7-year follow-up. | 207 |
| 5 | High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850391
The objective of this study was to determine whether high-dose intravenous vitamin C improves a composite of 28-day mortality and persistent organ dysfunction in patients with severe burn injury. | 374 |
| 6 | High-Dose Intravenous Vitamin C in Severe Burn Injury
https://jamanetwork.com/journals/jama/fullarticle/2850392
This international randomized clinical trial evaluates the efficacy of high-dose intravenous vitamin C in reducing 28-day mortality and persistent organ dysfunction (dependence on mechanical ventilation, kidney replacement therapy, or vasopressor/inotrope support at day 28) in patients with severe burn injury. | 369 |
| 7 | High-Dose Vitamin C in Burns
https://jamanetwork.com/journals/jama/fullarticle/2850393
In this issue of JAMA, Stoppe and colleagues present the results of an international randomized clinical trial that provides evidence that high-dose intravenous vitamin C does not improve outcomes in patients with large burns. The data from the VICTORY trial even suggest that use of vitamin C in patients with large burns might increase mortality. This well-designed study had strict criteria for stopping based on futility or harm. It is clear that the possibility of vitamin C improving outcomes in major burns is extremely low. | 349 |
| 8 | Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850074
This randomized clinical trial evaluates whether a reperfusion-guided systolic blood pressure control strategy improves functional outcomes compared with guideline-recommended management after successful endovascular therapy for acute ischemic stroke. | 630 |
| 9 | Pathology and Genetics in a Global Cohort of Parkinsonian Disorders
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850075
This cross-sectional study investigates how genetic variants and neuropathology are associated with clinical features and diagnostic accuracy in movement disorders. | 603 |
| 10 | Self-Reported Seizure Durations
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850076
This cohort study examines the range of self-reported seizure durations from more than 18 000 children and adults. | 549 |
| 11 | Missing Funding/Support and Role of the Funder Statement
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850077
In the Original Investigation titled “Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-Analysis,” published online on May 4, 2026, the Funding/Support and Role of the Funder/Sponsor acknowledgments were missing in the Article Information. The work was funded by a grant from Parkinson’s UK. This information has been added, in addition to the Role of the Funder/Sponsor. This article has been corrected online. | 506 |
| 12 | Survivors of Cyanotic Congenital Heart Disease: A Review
https://jamanetwork.com/journals/jama/fullarticle/2850177
This Review discusses the pathophysiology of cardiovascular complications in adults with cyanotic congenital heart disease after early management and examines late complications and management strategies. | 438 |
| 13 | Evaluating Inflammatory Joint Pain in Older Adults
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850108
This Clinical Insights discusses inflammatory arthritis in older adults and offers practical guidance. | 456 |
| 14 | Cognition After Postoperative Delirium
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850109
Postoperative delirium is common in older adults, but some of its long-term consequences remain debated. Its association with adverse outcomes is well established, including longer hospital stays, functional decline, institutionalization, and mortality. A more challenging question is whether delirium itself contributes to later cognitive decline or if it mainly identifies patients who already have frailty, have a health record that is medically complex, and are likely to become ill again. These competing explanations have distinct implications for care, including what we tell patients and families at discharge, how we plan follow-up, and how much emphasis we place on delirium prevention. In this issue of JAMA Internal Medicine, Hshieh et al provide data that help advance this debate. | 477 |
| 15 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850142
This study evaluated whether a once-weekly, 9-mg dose of mazdutide (combined with a reduced calorie diet and increased physical activity) leads to effective and safe weight reduction in Chinese adults with obesity (body mass index [BMI] ≥30) compared with placebo. | 561 |
| 16 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
https://jamanetwork.com/journals/jama/fullarticle/2850143
This randomized clinical trial compares the efficacy and safety of a 9-mg dose of mazdutide vs placebo in Chinese adults with obesity. | 535 |
| 17 | Insulin Costs and Use After the Inflation Reduction Act Out-of-Pocket Cap
https://jamanetwork.com/journals/jama/fullarticle/2850128
This interrupted time series analysis uses Medicare Part D data from January 2021 through December 2023 to measure changes in insulin cost and use after the Inflation Reduction Act $35 cap on out-of-pocket insulin costs, overall and for insulin users with previously high out-of-pocket cost. | 710 |
| 18 | Insulin Cost Caps and Pharmacoequity
https://jamanetwork.com/journals/jama/fullarticle/2850129
Diabetes incidence is rising in the US, with more than 40 million US residents living with this condition. Diabetes morbidity and mortality are unequally distributed, and new diagnoses are higher among American Indian/Alaska Native, Black, and Hispanic adults, compared with White adults. Managing prescription medications is critical to reducing diabetes morbidity, as is controlling risk factors and associated comorbid conditions. However, the cost of pharmacologic therapy has increased substantially, driven in part by the growing use of newer glucose-lowering agents. The high cost of these medications comprises a substantial portion of diabetes-related health care expenditure for individuals with diabetes and may result in restrictive coverage by health plans insuring enrollees with diabetes, further limiting access to care. The out-of-pocket costs faced by patients are particularly burdensome, because patients also face the consequences of adverse downstream outcomes that result from reduced medication adherence due to costs. | 702 |
| 19 | Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850123
This study evaluated whether finerenone, a nonsteroidal mineralocorticoid receptor antagonist, can slow loss of kidney function in patients with glomerular diseases. | 840 |
| 20 | Finerenone for CKD Due to Glomerular Diseases
https://jamanetwork.com/journals/jama/fullarticle/2850124
This exploratory analysis of a randomized clinical trial evaluates the efficacy and safety of finerenone in reducing chronic kidney disease of participants with glomerular diseases, including disease subtype. | 795 |
